MorphoSys announces that the first patient has been dosed in a phase 1b study of tafasitamab in newly diagnosed diffuse large B cell lymphoma
- Co announces that the first patient has been dosed in a phase 1b clinical study of MorphoSys' proprietary human anti-CD19 antibody tafasitamab in newly diagnosed diffuse large B cell lymphoma (DLBCL).
- "Based on the encouraging results we have seen so far with tafasitamab in relapsed and refractory DLBCL, we are now looking forward to explore the potential of tafasitamab in addition toR-CHOP or lenalidomide and R-CHOP in newly diagnosed DLBCL."
- This phase 1b study forms the basis for a subsequent pivotal phase 3 study in front line DLBCL